Cabaletta Bio (CABA) Liabilities and Shareholders Equity (2018 - 2025)

Cabaletta Bio's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $165.1 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 10.79% year-over-year to $165.1 million; the TTM figure through Dec 2025 stood at $744.5 million (down 12.14% YoY), while the FY2025 annual figure was $165.1 million, down 10.79% from the prior year.
• Liabilities and Shareholders Equity was $165.1 million for Q4 2025 at Cabaletta Bio, down from $189.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $253.6 million in Q4 2023 to a low of $91.7 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $159.7 million across 5 years, with a median of $165.1 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 132.44% in 2024, then plunged 31.32% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $126.3 million in 2021, then declined by 7.42% to $117.0 million in 2022, then jumped by 116.85% to $253.6 million in 2023, then declined by 27.05% to $185.0 million in 2024, then slipped by 10.79% to $165.1 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $165.1 million (Q4 2025), $189.8 million (Q3 2025), and $224.5 million (Q2 2025), per Business Quant data.